Results 191 to 200 of about 1,278 (247)
Which Patients With Dysfunctional Voiding Respond Well to Sacral Neuromodulation? ICI‐RS 2025
ABSTRACT Aims Dysfunctional voiding (DV) is characterised by fluctuating or intermittent urinary flow during voiding in neurologically normal individuals. Given the different definitions used and heterogeneous pathophysiologies, outcomes following sacral neuromodulation/sacral nerve stimulation (SNM/SNS) are variably reported.
Jalesh N. Panicker +8 more
wiley +1 more source
ABSTRACT Aims Neurogenic lower urinary tract dysfunction (NLUTD) describes a wide range of symptoms depending on neurologic diagnosis and the resulting bladder and sphincter dysfunction. This narrative review is designed to address the question regarding which NLUTD population benefits most from pelvic floor therapy and behavioral interventions, and ...
Sara M. Lenherr
wiley +1 more source
ABSTRACT Background and Objective Urinary incontinence (UI) is common in women. For up to 77%, the use of absorbent continence products (pads) is central to management. Pad changes are common and reasons for change are not fully described. We hypothesized that women change their pads for many reasons other than wetness and at saturation levels well ...
Sarah Qureshi +2 more
wiley +1 more source
Abstract Background Esophagectomy causes anatomical changes that can lead to rapid food transit and reactive hypoglycemia (RH). Patients are advised on eating patterns postesophagectomy to prevent RH, but its true incidence and the impact of dietary recommendations remain under‐researched.
Rachel O'Kelly +9 more
wiley +1 more source
Abstract Background Temporary feeding tubes are common in pediatric healthcare, but research on understanding how clinicians manage their use and understand the impact on families is limited. Existing research often overlooks clinician perspectives despite tensions between clinical priorities and family needs. This study aimed to understand clinicians'
Claire Reilly +4 more
wiley +1 more source
Weight Loss With GLP‐1 Agonists in Nondiabetic Adults: Systematic Review and Network Meta‐Analysis
ABSTRACT Objective Two glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) (semaglutide and liraglutide) and one dual agonist (tirzepatide) are FDA‐approved for weight loss in adults with obesity without type 2 diabetes mellitus. This systematic review and network meta‐analysis aims to compare the efficacy of these agents against each other.
Michael Lim +3 more
wiley +1 more source

